Hypertension Journal

Register      Login

VOLUME 1 , ISSUE 1 ( July-September, 2015 ) > List of Articles


Catheter-based Renal Denervation for Therapy of Hypertension: Is There a Hope for Its Resurgence?

Sebastian Ewen, Lucas Lauder, Michael Böhm, Felix Mahfoud

Keywords : Hypertension,Renal denervation,Symplicity,Therapy resistance

Citation Information : Ewen S, Lauder L, Böhm M, Mahfoud F. Catheter-based Renal Denervation for Therapy of Hypertension: Is There a Hope for Its Resurgence?. Hypertens J 2015; 1 (1):45-50.

DOI: 10.5005/jp-journals-10043-0008

Published Online: 01-09-2016

Copyright Statement:  Copyright © 2015; The Author(s).


How to cite this article

Ewen S, Lauder L, Böhm M, Mahfoud F. Catheter-based Renal Denervation for Therapy of Hypertension: Is There a Hope for Its Resurgence? Hypertens J 2015;1(1):45-50.

PDF Share
  1. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365(9455):217-223.
  2. Resistant hypertension: diagnosis, evaluation and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117(25):e510-526.
  3. Apparent and true resistant Hypertension: definition, prevalence and outcomes. J Hum Hypertens 2014;28(8):463-468.
  4. 2007 Guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-1187.
  5. Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int 2011;108(43):725-731.
  6. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009;54(4):690-697.
  7. Sympathorenal axis in chronic disease. Clin Res Cardiol 2011;100(12):1049-1057.
  8. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012;33(9):1058-1066.
  9. Physiology in perspective: the Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 2005;289(3):R633-641.
  10. Anatomic assessment of sympathetic periarterial renal nerves in man. J Am Coll Cardiol 2014;64(7):635-643.
  11. Innervation patterns may limit response to endovascular renal denervation. J Am Coll Cardiol 2014;64(11):1079-1087.
  12. Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol 2014;64(7):644-646.
  13. TCT-412 Noninvasive renal denervation using externally delivered focused ultrasound: early experience using doppler based imaging tracking and targeting for treatment. J Am Coll Cardiol 2014;64(11 Suppl):B121.
  14. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373(9671):1275-1281.
  15. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376(9756):1903-1909.
  16. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013;128(2):132-140.
  17. Invasive treatment of resistant hypertension: present and future. Current Hypertension Reports 2014;16(11):488.
  18. First Report of the Global Symplicity registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015;65(4):766-774.
  19. A controlled trial of renal denervation for resistant Hypertension. N Engl J Med 2014;370(15):1393-1401.
  20. From Symplicity HTN-3 to the renal denervation global registry: where do we stand and where should we go? Euro Inter-vention 2014;10(1):21-23.
  21. Renal denervation: symply trapped by complexity? Eur Heart J 2015;36(4):199-202.
  22. Predictors of blood pressure response in the Symplicity HTN-3 trial. Eur Heart J 2015;36(4):219-227.
  23. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 2015;65(6):1202-1208.
  24. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. The Lancet 2015;385(9981): 1957-1965.
  25. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the prague-15 study. Hypertension 2015;65(2):407-413.
  26. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013;34(28):2149-2157.
  27. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. European Heart J 2015;ehv192.
  28. Assessment of human sympathetic nervous system activity from measurements of norepine-phrine turnover. Hypertension 1988;11(1):3-20.
  29. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001;37(3):869-874.
  30. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension 2015;65(1):193-199.
  31. Comparison of the effects of anti-hypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009;54(2):409-413.
  32. Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. Euro Intervention 2015;11(1):110-116.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.